Francois Brisebois
Stock Analyst at Oppenheimer
(2.33)
# 2,604
Out of 5,111 analysts
87
Total ratings
40.91%
Success rate
0.8%
Average return
Main Sectors:
Stocks Rated by Francois Brisebois
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AQST Aquestive Therapeutics | Maintains: Outperform | $7 → $8 | $5.82 | +37.46% | 3 | Sep 8, 2025 | |
| SVRA Savara | Maintains: Outperform | $5 → $6 | $6.43 | -6.69% | 6 | Aug 15, 2025 | |
| SNSE Sensei Biotherapeutics | Maintains: Outperform | $70 → $80 | $8.08 | +890.10% | 2 | Mar 28, 2025 | |
| ABEO Abeona Therapeutics | Initiates: Outperform | $16 | $5.00 | +220.00% | 1 | Mar 5, 2025 | |
| OVID Ovid Therapeutics | Upgrades: Outperform | $4 | $1.55 | +158.06% | 1 | Jan 29, 2025 | |
| TARS Tarsus Pharmaceuticals | Maintains: Outperform | $65 → $72 | $78.28 | -8.02% | 7 | Jan 22, 2025 | |
| HRMY Harmony Biosciences Holdings | Maintains: Outperform | $59 → $61 | $38.83 | +57.10% | 6 | Jan 13, 2025 | |
| MNMD Mind Medicine (MindMed) | Reiterates: Outperform | $20 | $12.26 | +63.13% | 4 | Dec 17, 2024 | |
| TRDA Entrada Therapeutics | Maintains: Outperform | $25 → $28 | $11.37 | +146.26% | 2 | Nov 6, 2024 | |
| AVDL Avadel Pharmaceuticals | Maintains: Outperform | $29 → $30 | $21.37 | +40.38% | 8 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $143 → $163 | $274.51 | -40.62% | 4 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $55 | $19.55 | +181.33% | 5 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $15 | $0.56 | +2,599.78% | 2 | Aug 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $6 | $8.76 | -31.51% | 5 | Aug 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $11 | $4.38 | +151.14% | 6 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $25.72 | -45.57% | 2 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $55 → $65 | $18.86 | +244.64% | 5 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $10 | $5.31 | +88.32% | 2 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $152 | $6.66 | +2,182.28% | 2 | Aug 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $63 → $36 | $18.77 | +91.85% | 4 | Aug 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $100 → $60 | $0.12 | +49,816.81% | 3 | Apr 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $7,200 → $5,400 | $1.57 | +343,849.04% | 2 | Feb 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $17 → $11 | $3.56 | +208.99% | 2 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $18 | $3.36 | +435.71% | 1 | Jul 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $6.39 | +682.47% | 1 | Oct 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $3,240 | $0.98 | +330,579.73% | 1 | Feb 4, 2020 |
Aquestive Therapeutics
Sep 8, 2025
Maintains: Outperform
Price Target: $7 → $8
Current: $5.82
Upside: +37.46%
Savara
Aug 15, 2025
Maintains: Outperform
Price Target: $5 → $6
Current: $6.43
Upside: -6.69%
Sensei Biotherapeutics
Mar 28, 2025
Maintains: Outperform
Price Target: $70 → $80
Current: $8.08
Upside: +890.10%
Abeona Therapeutics
Mar 5, 2025
Initiates: Outperform
Price Target: $16
Current: $5.00
Upside: +220.00%
Ovid Therapeutics
Jan 29, 2025
Upgrades: Outperform
Price Target: $4
Current: $1.55
Upside: +158.06%
Tarsus Pharmaceuticals
Jan 22, 2025
Maintains: Outperform
Price Target: $65 → $72
Current: $78.28
Upside: -8.02%
Harmony Biosciences Holdings
Jan 13, 2025
Maintains: Outperform
Price Target: $59 → $61
Current: $38.83
Upside: +57.10%
Mind Medicine (MindMed)
Dec 17, 2024
Reiterates: Outperform
Price Target: $20
Current: $12.26
Upside: +63.13%
Entrada Therapeutics
Nov 6, 2024
Maintains: Outperform
Price Target: $25 → $28
Current: $11.37
Upside: +146.26%
Avadel Pharmaceuticals
Oct 31, 2024
Maintains: Outperform
Price Target: $29 → $30
Current: $21.37
Upside: +40.38%
Oct 31, 2024
Maintains: Outperform
Price Target: $143 → $163
Current: $274.51
Upside: -40.62%
Sep 3, 2024
Reiterates: Outperform
Price Target: $55
Current: $19.55
Upside: +181.33%
Aug 19, 2024
Reiterates: Outperform
Price Target: $15
Current: $0.56
Upside: +2,599.78%
Aug 16, 2024
Reiterates: Outperform
Price Target: $6
Current: $8.76
Upside: -31.51%
Aug 15, 2024
Reiterates: Outperform
Price Target: $11
Current: $4.38
Upside: +151.14%
Aug 14, 2024
Reiterates: Outperform
Price Target: $14
Current: $25.72
Upside: -45.57%
Jun 13, 2024
Maintains: Outperform
Price Target: $55 → $65
Current: $18.86
Upside: +244.64%
May 6, 2024
Reiterates: Outperform
Price Target: $10
Current: $5.31
Upside: +88.32%
Aug 30, 2023
Reiterates: Outperform
Price Target: $152
Current: $6.66
Upside: +2,182.28%
Aug 17, 2023
Maintains: Outperform
Price Target: $63 → $36
Current: $18.77
Upside: +91.85%
Apr 3, 2023
Maintains: Outperform
Price Target: $100 → $60
Current: $0.12
Upside: +49,816.81%
Feb 6, 2023
Maintains: Outperform
Price Target: $7,200 → $5,400
Current: $1.57
Upside: +343,849.04%
Aug 29, 2022
Maintains: Outperform
Price Target: $17 → $11
Current: $3.56
Upside: +208.99%
Jul 18, 2022
Assumes: Outperform
Price Target: $18
Current: $3.36
Upside: +435.71%
Oct 29, 2021
Initiates: Outperform
Price Target: $50
Current: $6.39
Upside: +682.47%
Feb 4, 2020
Initiates: Buy
Price Target: $3,240
Current: $0.98
Upside: +330,579.73%